Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sahlin, L.
Right arrow Articles by Blanck, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sahlin, L.
Right arrow Articles by Blanck, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Molecular Human Reproduction, Vol. 6, No. 1, 60-67, January 2000
© 2000 European Society of Human Reproduction and Embryology

Uterus and pregnancy

Thioredoxin expression in human myometrium and fibroids

L. Sahlin1,5, H. Wang1, B. Lindblom2, H. Eriksson1, A. Holmgren3 and A. Blanck4

1 Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Hospital L5:01, S-171 76 Stockholm, 2 Department of Women's and Children's Health, Section for Obstetrics and Gynecology, Uppsala University Hospital, S-751 85 Uppsala, 3 Medical Nobel Institute for Biochemistry, Department of Biochemistry and Biophysics, Karolinska Institute, S-171 77 Stockholm and 4 Department of Clinical Sciences, Division for Obstetrics and Gynecology, Huddinge Hospital, S-141 86 Huddinge, Sweden

Abstract

Thioredoxin is a small multifunctional protein which acts as a dithiol hydrogen donor for ribonucleotide reductase in DNA synthesis. Thioredoxin participates in the regulation of different metabolic processes, such as changes in the activity of different enzymes, receptors or transcription factors. The aim of the present study was to determine possible differences in the expression of thioredoxin between myometrium and fibroids in women during different periods of life. Thioredoxin mRNA concentrations were determined in myometrial and fibroid tissues obtained from women during the menstrual cycle, during treatment with an analogue of gonadotrophin releasing hormone (GnRH agonist), in the postmenopausal period (PMP) and during pregnancy. The concentration of thioredoxin mRNA was measured by a solution hybridization method. The localization of thioredoxin protein was examined by immunohistochemistry. There were significantly lower levels of thioredoxin expression in both fibroids and myometrium from GnRH agonist treated and PMP women in comparison with the pregnant women. No difference in thioredoxin expression was found between myometrium and fibroids from the same woman or between myometria from uteri with or without fibroids in the same patient group. Thioredoxin expression in uterine fibroids does not seem to be up-regulated, but changes in response to the endocrine conditions in a similar way to that observed in the myometrium.

fibroids/GnRH agonist/redox regulation/thioredoxin uterus

Notes

5 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Orii, H. Masutani, T. Nikaido, Y.-L. Zhai, K. Kato, M. Kariya, I. Konishi, J. Yodoi, and S. Fujii
Altered Post-Translational Modification of Redox Factor 1 Protein in Human Uterine Smooth Muscle Tumors
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3754 - 3759.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.